147.10USD+4.76%Mkt Cap: 5.89B USDP/E: —Last update: 2026-06-01
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tin…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap5.89B USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-77.61M USD
Revenue/Share—
Last Price147.10 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)152.69
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B7.13
EPS (TTM)-2.55
EPS (Forward)0.94
52W Range
56.1063% of range200.00
52W High200.00 USD
52W Low56.10 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-10.07%
ROA-9.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.99M USD
CapEx (TTM)178.00K USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio33.71
Quick Ratio—
Book Value/Sh20.23 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)210.50 USD
Target Range185.00 USD – 266.00 USD
# Analysts8
Ownership
Shares Out.40.09M
Float18.48M
Insiders44.27%
Institutions23.68%
Short Interest
Short Ratio10.2d
Short % Float5.72%
Short % Out.2.97%
Shares Short1.19M
Short (prev mo.)1.11M
Technical
SMA 50157.48 (-6.6%)
SMA 200132.68 (+10.9%)
Beta-1.19
S&P 52W Chg27.94%
Avg Vol (30d)135.84K
Avg Vol (10d)206.12K
Technical Indicators
RSI (14)38.6
MACD-5.3244
MACD Signal-5.2337
MACD Hist.-0.0907
BB Upper161.43 USD
BB Middle148.00 USD
BB Lower134.57 USD
BB Width18.15%
ATR (14)7.434 USD
Vol Ratio (20d)3.22x